Analysts Set GSK plc (LON:GSK) Target Price at GBX 2,048.57

GSK plc (LON:GSK) has received a consensus recommendation of “Hold” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is GBX 2,048.57.

A number of research analysts have recently weighed in on the stock. Citigroup cut their price target on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 2,000 target price on shares of GSK in a report on Tuesday, August 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th.

Insider Buying and Selling

In related news, insider Vishal Sikka purchased 1,266 shares of the stock in a transaction on Monday, June 22nd. The shares were bought at an average price of GBX 5,069 per share, for a total transaction of £64,173.54. Also, insider Jonathan Symonds bought 1,550 shares of the company’s stock in a transaction that occurred on Friday, June 19th. The stock was purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. In the last ninety days, insiders purchased 3,618 shares of company stock worth $13,481,942. 0.20% of the stock is currently owned by insiders.

GSK Trading Up 0.4%

Shares of LON GSK opened at GBX 1,858.50 on Tuesday. The stock has a market cap of £74.44 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 1.24 and a beta of 0.29. The business has a 50 day simple moving average of GBX 1,939.39 and a 200 day simple moving average of GBX 1,997.93. GSK has a 52 week low of GBX 1,288.61 and a 52 week high of GBX 2,282. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. On average, research analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.